Novel genes associated with lymph node metastasis in triple negative breast cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Mathe, Andrea ^a,b   Wong Brown, Michelle ^a,b   Morten, Brianna ^a,b   Forbes, John F ^b,c,d   Braye, Stephen G ^e   Avery Kiejda, Kelly A ^a,b   Scott, Rodney J ^a,b,e  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

ADULT; AGED; BREAST; CELL DEATH; CHROMOSOMAL INSTABILITY; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETICS; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST; CELL DEATH; CHROMOSOMAL INSTABILITY; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; PROGNOSIS; RECOMBINATION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84946733914     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15832     Document Type: Article

References (65)

1. Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7, 683-92 (2010).
2. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the california cancer registry. Cancer 109, 1721-8 (2007).
3. Reis-Filho, J. S. & Tutt, A. N. Triple negative tumours: a critical review. Histopathology 52, 108-18 (2008).
4. Dent, R. et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115, 423-8 (2009).
5. Chaffer, C. L. & Weinberg, R. A. A Perspective on cancer cell metastasis. Science 331, 1559-64 (2011).
6. Cho, H. M. et al. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med 2, 963-967 (2011).
7. Tucci, P. et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 109, 15312-7 (2012).
8. Peddi, P. F., Ellis, M. J. & Ma, C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012, 217185 (2012).
9. Anders, C. K. et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res 16, 4702-10 (2010).
10. Beezhold, K. J., Castranova, V. & Chen, F. Microprocessor of microRNAs: regulation and potential for therapeutic intervention. Mol Cancer 9, 134 (2010).
11. Zhang, J. & Ma, L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev 31, 653-62 (2012).
12. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-66 (2006).
13. Farazi, T. A. et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71, 4443-53 (2011).
14. Janssen, E. A. et al. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol 23, 1567-76 (2010).
15. Volinia, S. et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 109, 3024-9 (2012).
16. Avery-Kiejda, K. A., Braye, S. G., Mathe, A., Forbes, J. F. & Scott, R. J. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC cancer 14, 51 (2014).
17. Cascione, L. et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8, e55910 (2013).
18. Prensner, J. R. & Chinnaiyan, A. M. The emergence of lncRNAs in cancer biology. Cancer Discov 1, 391-407 (2011).
19. Blenkiron, C. et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8, R214 (2007).
20. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
21. Chacón, R. D. & Costanzo, M. V. Triple-negative breast cancer. Breast Cancer Res 12 Suppl 2, S3 (2010).
22. Carotenuto, P. et al. Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit Rev Eukaryot Gene Expr 20, 17-34 (2010).
23. Kuo, W. H. et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One 7, e45831 (2012).
24. Yau, C. et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12, R85 (2010).
25. Rakha, E. A. et al. Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32 (2007).
26. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429-34 (2007).
27. Atkinson, R. L. et al. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res 15, R77 (2013).
28. Braakhuis, B. J., Leemans, C. R. & Brakenhoff, R. H. Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice. J Pathol 203, 620-1 (2004).
29. Hartman, Z. C. et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73, 3470-80 (2013).
30. Tozlu, S. et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13, 1109-20 (2006).
31. Wilson, B. J. & Giguere, V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 7, 49 (2008).
32. Nissan, A. et al. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer 94, 681-5 (2006).
33. Jager, D. et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 61, 2055-61 (2001).
34. Seil, I. et al. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer 120, 2635-42 (2007).
35. Varga, Z. et al. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res 12, 2745-51 (2006).
36. Obri, A. et al. ANP32E is a histone chaperone that removes H2A.Z from chromatin. Nature 505, 648-53 (2014).
37. Billon, P. & Cote, J. Precise deposition of histone H2A.Z in chromatin for genome expression and maintenance. Biochim Biophys Acta 1819, 290-302 (2013).
38. Conerly, M. L. et al. Changes in H2A.Z occupancy and DNA methylation during B-cell lymphomagenesis. Genome Res 20, 1383-90 (2010).
39. Hua, S. et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 4, 188 (2008).
40. Landemaine, T. et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res 68, 6092-9 (2008).
41. Culhane, A. C. & Quackenbush, J. Confounding effects in "A six-gene signature predicting breast cancer lung metastasis". Cancer Res 69, 7480-5 (2009).
42. Dusek, R. L., Godsel, L. M. & Green, K. J. Discriminating roles of desmosomal cadherins: beyond desmosomal adhesion. J Dermatol Sci 45, 7-21 (2007).
43. Karczewska, A., Nawrocki, S., Breborowicz, D., Filas, V. & Mackiewicz, A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 88, 2061-71 (2000).
44. Bajo-Graneras, R. et al. Expression and potential role of apolipoprotein D on the death-survival balance of human colorectal cancer cells under oxidative stress conditions. Int J Colorectal Dis 28, 751-66 (2013).
45. Sarjeant, J. M. et al. Apolipoprotein D inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferated by preventing translocation of phosphorylated extracellular signal regulated kinase 1/2 to the nucleus. Arterioscler Thromb Vasc Biol 23, 2172-7 (2003).
46. Do Carmo, S., Levros, L. C., Jr. & Rassart, E. Modulation of apolipoprotein D expression and translocation under specific stress conditions. Biochim Biophys Acta 1773, 954-69 (2007).
47. Soiland, H. et al. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer-possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients. Acta Oncol 48, 514-21 (2009).
48. Mattick, J. S. & Makunin, I. V. Non-coding RNA. Hum Mol Genet 15 Spec No 1, R17-29 (2006).
49. Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-6 (2010).
50. Wang, P., Ren, Z. & Sun, P. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem 113, 1868-74 (2012).
51. Sun, M. et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35, 1065-73 (2014).
52. Qin, R. et al. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 60, 486-92 (2013).
53. Ying, L. et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst 9, 407-11 (2013).
54. Buffa, F. M. et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71, 5635-45 (2011).
55. Sempere, L. F. et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67, 11612-20 (2007).
56. Piovan, C. et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6, 458-72 (2012).
57. Berber, U. et al. miR-205 and miR-200c: predictive micro rnas for lymph node metastasis in triple negative breast cancer. J Breast Cancer 17, 143-8 (2014).
58. Bouchalova, K., Cizkova, M., Cwiertka, K., Trojanec, R. & Hajduch, M. Triple negative breast cancer-current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153, 13-7 (2009).
59. Lan, J. et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumour Biol 35, 179-87 (2014).
60. Podo, F. et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4, 209-29 (2010).
61. Al-Ejeh, F. et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 3, e100 (2014).
62. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38, 1043-8 (2006).
63. Huang, E. et al. Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-6 (2003).
64. Szasz, A. M. et al. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS One 8, e56707 (2013).
65. Avery-Kiejda, K. A., Morten, B., Wong-Brown, M. W., Mathe, A. & Scott, R. J. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis 35, 586-96 (2014).